A defensible diagnostics supplier in a cyclical trough—pivoting to high-margin QAPs while holding a free, non-dilutive Kinlytic royalty call option.
Overview
Microbix Biosystems (TSX: MBX) is a specialized B2B life-sciences manufacturer embedded in the global infectious-disease diagnostics supply chain, serving 100+ OEMs and accreditation/lab customers across 30+ countries with ~100–120 employees. The business has three diagnostics segments: (1) Antigens—scaled cultivation and inactivation of native/recombinant pathogens used as immunoassay inputs; historically the largest segment with recurring OEM demand supported by regulatory switching friction. (2) QAPs™—proprietary “patient-sample mimetics” used as controls for MDx/antigen tests in EQA programs, proficiency testing, and POCT validation; sold as liquid controls and in a differentiated Copan FLOQSwab format and increasingly embedded/white-labeled in OEM kits, creating sticky, higher-margin recurring revenue. (3) Viral Transport Medium (DxTM™)—a COVID-era windfall product now a negligible contributor but with intact capacity. Separately, Microbix owns global rights to Kinlytic® (Urokinase), an FDA-approved thrombolytic for clearing occluded catheters, commercialized via Sequel Pharma: Sequel funds regulatory/manufacturing, while Microbix receives milestones and double-digit royalties—creating asymmetric upside without draining core capital.